LifeStance Health Group, Inc. (LFST)
| Market Cap | 3.32B +44.6% |
| Revenue (ttm) | 1.49B +16.5% |
| Net Income | 23.20M |
| EPS | 0.06 |
| Shares Out | 387.83M |
| PE Ratio | 145.48 |
| Forward PE | 55.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 499,250 |
| Open | 8.51 |
| Previous Close | 8.50 |
| Day's Range | 8.36 - 8.59 |
| 52-Week Range | 3.74 - 8.89 |
| Beta | 1.19 |
| Analysts | Buy |
| Price Target | 10.55 (+23.1%) |
| Earnings Date | May 7, 2026 |
About LFST
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic str... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for LFST stock is "Buy." The 12-month stock price target is $10.55, which is an increase of 23.10% from the latest price.
News
LifeStance initiated with a Neutral at Goldman Sachs
Goldman Sachs initiated coverage of LifeStance (LFST) with a Neutral rating and $9 price target As one of the largest pure-play providers of outpatient mental health services in the United…
LifeStance Health Group Transcript: 46th Annual William Blair Growth Stock Conference
Outpatient mental health demand is rising, with consolidation and payer pressure improving access and affordability. A hybrid care model, broad service offerings, and strong financials support rapid growth and industry leadership, with a focus on quality outcomes and geographic expansion.
LifeStance price target raised to $9 from $8 at JPMorgan
JPMorgan raised the firm’s price target on LifeStance (LFST) to $9 from $8 and keeps a Neutral rating on the shares.
LifeStance Health Group Transcript: Bank of America Global Healthcare Conference 2026
Outpatient mental health is experiencing strong growth, with rising demand, reduced stigma, and a shift to insurance-based care. A hybrid, large-scale provider is achieving high patient satisfaction, strong financial performance, and targets mid-teens EBITDA margins by 2028.
LifeStance price target raised to $12 from $11 at BTIG
BTIG raised the firm’s price target on LifeStance (LFST) to $12 from $11 and keeps a Buy rating on the shares after its Q1 earnings beat. The company continues to…
LifeStance price target raised to $11 from $10 at Canaccord
Canaccord raised the firm’s price target on LifeStance (LFST) to $11 from $10 and keeps a Buy rating on the shares. The firm said they posted an Impressive, clean quarter…
LifeStance Health Group Announces Pricing of Secondary Public Offering
SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation's largest providers of virtual and in-person outpati...
LifeStance announces offering of 35M shares of common stock for holders
LifeStance (LFST) Health Group announced that pursuant to a shelf registration statement filed with the SEC, certain stockholders of the company intend to offer 35M shares of LifeStance’s common stock...
LifeStance Health Group Announces Launch of Secondary Public Offering
SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation's largest providers of virtual and in-person outpati...
LifeStance Health Group Earnings Call Transcript: Q1 2026
Revenue grew 21% to $403M with adjusted EBITDA up 48% and net income at $14M. Clinician base and productivity rose, driving raised full-year guidance. Technology and AI investments, strong specialty growth, and robust cash flow position the company for continued expansion.
LifeStance Health Group Earnings release: Q1 2026
LifeStance Health Group released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
LifeStance Health Group Slides: Q1 2026
LifeStance Health Group has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
LifeStance Health Group Quarterly report: Q1 2026
LifeStance Health Group has published its Q1 2026 quarterly earnings report on May 7, 2026.
LifeStance Reports First Quarter 2026 Results
SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial resul...
LifeStance to Present at Upcoming Investor Conferences
SCOTTSDALE, Ariz., April 29, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced that manageme...
LifeStance to replace Golden Entertainment in S&P 600 at open on 5/1
LifeStance Health Group (LFST) will replace Golden Entertainment (GDEN) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, May 1. VICI Properties (VICI) and Blake…
LifeStance Health Group Proxy statement: Proxy filing
LifeStance Health Group filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
LifeStance Health Group Proxy statement: Proxy filing
LifeStance Health Group filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
LifeStance Publishes Outcomes Data Validating the Benefit of Mental Health Treatment at Scale
Analysis of 180,000 Patients Validates Measurement-Informed Care for Anxiety and Depression SCOTTSDALE, Ariz., April 9, 2026 /PRNewswire/ -- LifeStance Health, one of the nation's largest providers of...
LifeStance price target raised to $9 from $8 at Barclays
Barclays raised the firm’s price target on LifeStance (LFST) to $9 from $8 and keeps an Overweight rating on the shares. The firm remains “optimistic” that the company’s recent investments…
LifeStance price target raised to $10 from $9 at Canaccord
Canaccord analyst Richard Close raised the firm’s price target on LifeStance (LFST) to $10 from $9 and keeps a Buy rating on the shares. The firm said 4Q and 2026…
LifeStance price target raised to $12 from $10 at UBS
UBS raised the firm’s price target on LifeStance (LFST) to $12 from $10 and keeps a Buy rating on the shares. LifeStance posted another solid quarter, the analyst tells investors…
LifeStance price target raised to $9 from $8 at KeyBanc
KeyBanc analyst Steve Dechert raised the firm’s price target on LifeStance (LFST) to $9 from $8 and keeps an Overweight rating on the shares. The firm notes the company reported…
LifeStance announces 25M share offering of common stock for holders
LifeStance (LFST) Health Group announced that pursuant to a shelf registration statement filed with the SEC, certain stockholders of the company intend to offer 25M shares of LifeStance’s common stock...
LifeStance price target raised to $10 from $8 at BMO Capital
BMO Capital raised the firm’s price target on LifeStance (LFST) to $10 from $8 and keeps an Outperform rating on the shares.